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The binding of HIV-derived recombinant soluble (s)gp120 to the CD41/CXCR41 A3.01 T cell line inhibits the binding of the
CXCR4-specific monoclonal antibodies 12G5, which interacts with the second extracellular loop, and 6H8, which binds the
NH2 terminus. We have used this as an assay to analyse the interaction of recombinant sgp120 from diverse viral origins with
CXCR4. The strength of the interaction between sgp120 and CXCR4 correlated with sgp120 affinity for the CD4–CXCR4
complex, and the interaction of sgp120MN and sgp120IIIB with CXCR4 was highly dependent on the level of CD4 expressed
on a variety of different T cell lines. sgp120 from X4, R5X4, and R5 viruses interacted with CXCR4, although the R5
sgp120–CXCR4 interactions were weaker than those of the other gp120s. The interaction of sgp120IIIB or sgp120MN with
CXCR4 was inhibited by neutralizing monoclonal antibodies that prevent the sgp120-CD4 interaction but also by antibodies
specific for the gp120 V2 and V3 loops, the CD4-induced epitope and the 2G12 epitope, which interfere weakly or not at all
with CD4-sgp120 binding. The binding to A3.01 cells of wild-type sgp120HxB2, but not of sgp120 deleted in the COOH and NH2
termini, interfered with 12G5 binding in a dose-dependent manner. Further deletion of the V1 and V2 loops restored CXCR4
binding activity, but additional removal of the V3 loop eliminated the gp120-CXCR4 interaction, without decreasing the affinity
between mutated sgp120 and CD4. Taken together, these results demonstrate that the interactions between sgp120 and
CXCR4 are globally similar to those previously observed between sgp120 and CCR5, with some apparent differences in the
strength of the sgp120-CXCR4 interactions and their dependence on CD4. © 1998 Academic Press
INTRODUCTION
Infection of receptor-bearing target cells by the human
immunodeficiency virus (HIV) requires interactions be-
tween the surface (SU) and transmembrane (TM) viral
envelope glycoproteins, gp120 and gp41, respectively,
and specific cell surface receptors. CD4 was the first
receptor identified for HIV-1, and it determines viral tro-
pism in vivo for CD41 T cells, macrophages, and den-
dritic cells (reviewed in Sattentau and Weiss, 1988; Levy,
1994; Bour et al., 1995). HIV binds CD4 via an interaction
between the CDR-2-like loop within the first domain of
CD4 and the CD4 binding site (CD4bs) on gp120 (re-
viewed in Sweet et al., 1991), resulting in the induction of
conformational changes in gp120 that are thought to be
important for gp41-driven virus-cell membrane fusion (re-
viewed in Moore et al., 1993; Sattentau and Moore, 1993;
Signoret et al., 1993). Interaction of gp120 with a member
of the recently defined HIV coreceptors is required for
membrane fusion to proceed (reviewed in Berger, 1997;
Doms and Peiper, 1997; Moore et al., 1997). These core-
ceptor molecules are members of the seven transmem-
brane (7TM), G-protein-coupled chemokine receptor
family (Berger, 1997; Doms and Peiper, 1997; Moore et
al., 1997). Of the growing number of 7TM molecules that
have HIV coreceptor function, two stand out as being of
primary importance. CXCR4, a receptor for the CXC che-
mokine SDF-1 (Bleul et al., 1996; Oberlin et al., 1996) was
the first 7TM receptor with HIV-1 coreceptor activity to be
identified (Feng et al., 1996). Viruses adapted to growth in
immortalized T cell lines or syncytium-inducing viruses
isolated from HIV-infected individuals were found to use
CXCR4 alone [X4 viruses (Berger et al., 1997)] or CXCR4
and CCR5 (R5X4 viruses [Berger et al., 1997)]. CCR5 is a
CC chemokine receptor that binds RANTES, MIP-1a and
MIP-1b (Alkhatib et al., 1996; Choe et al., 1996; Deng et
al., 1996; Doranz et al., 1996; Dragic et al., 1996) and is
the coreceptor most strongly implicated in HIV-1 trans-
mission, since individuals homozygous for an inactivat-
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ing deletion in the CCR5 gene are highly resistant to
HIV-1 infection (Liu et al., 1996; Paxton et al., 1996; Sam-
son et al., 1996).
The binding of gp120 to CD4 is thought to induce
conformational changes that expose a coreceptor bind-
ing site on gp120 (Trkola et al., 1996a; Wu et al., 1996).
Thus sgp120 from R5 viruses binds poorly to CCR5 in the
absence of CD4 but strongly when the sgp120 is pre-
complexed with soluble (s)CD4 (Wu et al., 1996). More-
over, the binding of sgp120 from CXCR4-using viruses to
CD41/CXCR41 cells results in the formation of a trimo-
lecular complex of sgp120, CD4, and CXCR4 (Lapham et
al., 1996; Ugolini et al., 1997b; Forster et al., 1998). sgp120
derived from viruses was poorly able or unable to inter-
act with CCR5 (Trkola et al., 1996a; Wu et al., 1996), and
likewise sgp120 from R5 viruses interacted less strongly
with CXCR4 (Ugolini et al., 1997b). Thus virus tropism for
cell types expressing different coreceptors may be in
part determined by gp120 binding affinity for these core-
ceptors. The most extreme example of this described to
date is the interaction of the SIV SU glycoprotein with
human or macaque CCR5 in a CD4-independent manner
(Martin et al., 1997), demonstrating a direct, efficient
association.
The gp120 V3 loop has been proposed to interact,
either directly or indirectly, with CCR5 (Choe et al., 1996;
Cocci et al., 1996; Wu et al., 1996), although a more
conserved region of gp120 may also be implicated (Sul-
livan et al., 1998). Moreover, antibodies to a number of
neutralizing epitopes on gp120 interfere with CCR5-
gp120 binding (Trkola et al., 1996a; Wu et al., 1996).
Despite the existing body of information describing the
interactions between or CCR5 gp120 and CXCR4 it is
unclear whether these two SU-coreceptor interactions
are analogous to one another or differ structurally and
functionally. For this reason, we have attempted to better
define the interactions between gp120 and CXCR4 by
using an assay based on the inhibition of CXCR4-specific
monoclonal antibodies (mAb) by sgp120. We demon-
strate that sgp120–CXCR4 interactions are dependent on
the SU affinity for the CD4-coreceptor complex, within
which the affinity for CD4 alone is clearly the dominant
association for cell surface binding. The viral origin of the
sgp120 and the level of cell surface CD4 expression also
influenced the gp120–CXCR4 interaction, which was in-
hibited by antibodies to all neutralizing epitopes tested,
and requires conservation of the gp120 COOH and NH2
termini, and the V3 loop.
RESULTS
Inhibition of CXCR4-specific mAb binding by different
SU glycoproteins
We demonstrated previously that the binding of
sgp120 molecules from diverse HIV-1 strains to the
CD41/CXCR41 T cell line A3.01 inhibited the binding of
the CXCR4-specific mAb 12G5 and that this was CD4-
dependent, since no inhibition was observed with the
CD42 variant line, A2.01 (Ugolini et al., 1997b). To better
understand the relationship between sgp120 binding to
cell surface CD4 and subsequent interactions between
CXCR4 and gp120, we titrated sgp120 of different viral
origins onto A3.01 cells, then measured the following
parameters; (1) sgp120 binding with an Env-specific poly-
clonal antibody; (2) occupation of the gp120 binding site
on CD4 by the inhibition of binding of the CD4-domain
1-specific mAb Q4120; and (3) inhibition of 12G5 binding.
The recombinant SU glycoprotein molecules used in this
study have the following coreceptor usage: IIIB and MN,
HIV-1 X4 (Feng et al., 1996; unpublished results); LAV-
2ROD, HIV-2 R5R3X4 (Sol et al., 1997); SF-2 and W61D,
R5X4 (Trkola et al., 1996a); Bal and JRFL, R5 (Trkola et al.,
1996a). The coreceptor usage of CM235 is not published,
but the V3 loop sequence suggests an R5 virus. Panel A
of Fig. 1 shows that the binding of sgp120 to A3.01 cells
was dose dependent and was saturating for SU of all
origins between 3 and 30 mg/ml with the exception of Bal
and CM235, which had lower affinities. The differences
between the Bmax values are probably the result of dif-
ferential binding of the detection antibody to the different
SU glycoproteins. To standardize measurement of bind-
ing to CD4 and to allow detection of gp105LAV-2 and
gp120 deletion mutants (see Fig. 6), we measured SU-
CD4 binding indirectly, by assay of the inhibition of CD4
mAb Q4120 binding: gp120 competes with Q4120 for
binding to D1 of CD4. As shown in Fig. 1B, Q4120 binding
decreased in proportion to the amount of sgp120 bound.
A statistical analysis demonstrated an excellent correla-
tion between direct detection of gp120 with HIVIg and
inhibition of Q4120 binding for the HIV-1 gp120s (r 5 0.97,
P , 0.0001), and for subsequent experiments inhibition
of Q4120 binding was used as a measure of gp120
binding. Figure 1C shows that the inhibition of 12G5
binding increases with sgp120 binding in a dose-depen-
dent manner. A wide range of inhibition was observed at
concentrations of gp120 saturating for CD4; HIV-2LAV-2
gp105 gave the greatest inhibition, whereas gp120Bal
gave the poorest. Visual inspection of the curves repre-
senting inhibition of 12G5 binding and inhibition of Q4120
binding suggest a relationship for all SUs, and a statis-
tical analysis confirmed that there is a strong correlation
(r 5 0.807, P , 0.0001). As expected, a correlation was
also seen between direct HIV-1 sgp120 detection by
HIVIg and 12G5 inhibition (r 5 0.778, P , 0.0001). No
relationship was observed between the type of recom-
binant SU glycoprotein tested (CHO cell or Drosophila
cell produced) and its CD4–CXCR4 affinity or ability to
inhibit 12G5 binding, suggesting that differences in gly-
cosylation do not strongly influence these interactions.
Maximum inhibition obtained in this experiment was
about 35% with sgp120LAV-2. In other experiments, we
saw greater inhibition (up to 50%, see Figs. 2 and 4),
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demonstrating some interexperimental variability. The
most likely explanation for this is the relatively variable
expression of the 12G5 epitope on A3.01 cells: modula-
tion of 12G5 staining will alter the ratio of CXCR4 to CD4
staining, potentially modifying the degree of sgp120 in-
hibition of 12G5 binding (see Fig. 4 and Discussion).
Weak inhibition of 12G5 binding to A3.01 cells by a
species of sgp120 that saturates essentially all CD4
molecules suggests that the affinity of this gp120 for
CXCR4 is low. However, an alternative explanation is that
such a gp120 may bind to a region of CXCR4 distant from
the 12G5 epitope and therefore interfere only weakly with
12G5 binding. To investigate this possibility, we tested
the inhibition of the 6H8 mAb specific for the NH2 termi-
nus of CXCR4. At 30 mg/ml, similar inhibition of both
12G5 and 6H8 were observed for most of the gp120s
tested (Fig. 2). In this experiment, only SF2 inhibited 12G5
significantly more than 6H8, but in other experiments, no
significant difference was seen. Thus it seems likely that
either gp120 molecules of different viral origin interact
with similar regions of CXCR4, or gp120 binding to
CXCR4 induces global conformational changes in CXCR4
that disrupt the binding of mAb to distinct epitopes on the
surface of this molecule. In either case, inhibition of
binding of either mAb seems likely to reflect the strength
of gp120 interaction with CXCR4, and, for subsequent
experiments, only the 12G5 mAb was used.
Western blotting of the HIV-1 sgp120 molecules
Overall, the above data suggest that the strength of the
sgp120–CXCR4 interaction varies according to the viral
origin of the SU glycoprotein and correlates with the
affinity between SU and the CD4–CXCR4 complex. Since
the gp120 V3 loop has been implicated in coreceptor
interactions, one possible explanation for the variable
binding to the receptor-coreceptor complex was differ-
ential cleavage by exogenous proteases of the V3 loops
of the different SU glycoproteins. For this reason, we
carried out Western blotting of the different gp120s after
migration under reducing conditions; gp120 cleaved in
the V3 loop migrates as two bands of 50 and 70 kDa
(Clements et al., 1991), and these cleavage products can
be detected by HIVIg (data not shown). Figure 3 demon-
strates that none of the gp120 molecules had undergone
significant cleavage of the V3 loop.
Cell type dependence of the SU-CD4-CXCR4
interaction
It has been shown previously that inhibition of X4
viruses by 12G5 is both virus isolate and cell type de-
pendent (McKnight et al., 1997). One explanation for this
phenomenon is that coreceptors other than CXCR4 might
be used by certain viruses on certain cell lines. We
therefore tested whether the cellular context influenced
the interaction among CD4, CXCR4, and gp120: if core-
FIG. 1. Interaction of sgp120 from different virus origins with CXCR4.
(A) A3.01 cells were incubated for 4 h at 4°C with concentrations of
sgp120 ranging from 0.1 to 30 mg/ml. After washing, bound gp120 was
detected directly with HIVIg, then labeled by indirect immunofluores-
cent staining and analysed by flow cytometry. (B) Bound gp120 was
detected indirectly by measurement of the inhibition of CD4 mAb Q4120
followed by indirect immunofluorescent staining and analysis as for (A),
and the results were expressed as percentage inhibition of maximum
Q4120 binding obtained in the absence of bound gp120. (C) gp120-
mediated inhibition of 12G5 was measured by reduction of 12G5 mAb
binding, determined by indirect immunofluorescent staining as for (B).
The experiment shown is representative of three independent experi-
ments. Each point represents the mean of triplicate values, and the
error bars in (A) represent 61 SD.
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ceptors other than CXCR4 were preferentially used on
some cell lines, then little or no interaction between
gp120 and CXCR4 might be observed on those lines. The
binding of two different sgp120 molecules to a panel of
CD41 T cell lines was measured by inhibition of Q4120
binding, and the interaction between sgp120 and CXCR4
was determined by inhibition of 12G5 (Fig. 4A). Figure 3
shows that under conditions in which 95–99% of all cell
surface CD4 molecules were occupied by gp120 (Fig. 4B)
and there was an excess of CD4/CXCR4 molecules of
more than fivefold on all lines except A2.01 (Fig. 4C),
there was a substantial difference between different
lines in terms of 12G5 inhibition (Fig. 4A). 12G5 inhibition
ranged from undetectable (H9 and A2.01) to a maximum
of about 45% (A3.01) with gp120MN. Comparison of the
sgp120MN and sgp120IIIB inhibition of 12G5 binding with
CXCR4 expression level (Fig. 3C) did not reveal a signif-
icant correlation (r 5 0.431, P 5 0.285 for MN; r 5 0.533,
P 5 0.1736 for IIIB), whereas CD4 expression was
strongly correlated with 12G5 inhibition (r 5 0.859, P 5
0.0063 for MN; r 5 0.863, P 5 0.0057 for IIIB). These data
imply that the determinant factor in the CXCR4–sgp120
interaction is the level of CD4 expression, making it
unlikely that other factors, such as the preferential use of
other chemokine receptors by gp120IIIB or gp120MN, play
a significant role.
Inhibition of the sgp120-CD4-CXCR4 interaction by
neutralizing mAbs
Previous studies demonstrated that the sgp120–CCR5
interaction could be disrupted by neutralizing antibodies
specific for several different epitopes and concluded that
all neutralizing mAb tested interfered with either the
CD4–gp120 interaction or the CCR5–gp120 interaction
(Trkola et al., 1996a; Wu et al., 1996; Hill et al., 1997). To
determine whether this was also true for CXCR4, we
attempted to prevent the gp120-mediated inhibition of
12G5 binding with mAbs specific for a variety of neutral-
izing epitopes. In parallel, we controlled for the ability of
the mAbs to interfere with gp120-CD4 binding, a factor
not evaluated in previous studies. mAbs and sgp120
were preincubated at an approximately 5:1 molar ratio
under conditions previously shown to result in saturation
of the gp120 molecules by mAb (Moore et al., 1995a;
Sattentau and Moore, 1995; unpublished results). As
FIG. 2. Inhibition of 12G5 and 6H8 binding by interaction of sgp120
with CXCR4. A3.01 cells were incubated for 4 h at 4°C with 30 mg/ml of
sgp120. (A) sgp120-mediated inhibition of 12G5 and 6H8 is shown as
percentage reduction in mAb binding, determined by indirect immuno-
fluorescent staining as for Fig. 1. Each bar represents the mean of
triplicate values, and the error bars indicate 61 SD. Bound gp120 (B)
was detected indirectly by measurement of the inhibition of CD4 mAb
Q4120 followed by indirect immunofluorescent staining and analysis as
in Fig. 1 and expressed as percentage inhibition of maximum Q4120
binding in the absence of bound gp120.
FIG. 3. Western blot of sgp120. sgp120 was migrated on a reducing
acrylamide gel before Western blotting. Proteins were detected with
HIVIg followed by anti-human horseradish peroxidase and chemolumi-
nescent substrate. The y axis represents the molecular weights tran-
scribed from the markers on the gel. Lanes 1–7 represent the following
gp120 molecules, respectively; IIIB, MN, W61D, SF2, JRFL, Bal, CM.
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shown in Fig. 5, the CD4bs-specific mAb IgG1b12 inhib-
ited both CD4 and CXCR4 interactions with gp120MN and
gp120IIIB by .90%. The CD4i epitope-specific mAbs 17b
and 48d partially interfered with gp120-CD4 binding, in-
hibiting gp120IIIB and gp120MN binding by about 50 and
20%, respectively, but strongly interfered with the gp120-
mediated inhibition of 12G5 binding (80–100%). These
data imply that mAbs to the CD4i epitope interfere with
the CXCR4–gp120 interaction in a manner partially inde-
pendent of CD4-gp120 binding. The mAb 447-52D rec-
ognizes a relatively well-conserved epitope at the tip of
the V3 loop and neutralizes both IIIB and MN strains of
HIV-1. Although this mAb did not significantly interfere
with CD4-gp120 binding, the gp120-mediated inhibition
of 12G5 binding was strongly inhibited (70 and 90% for
sgp120IIIB and sgp120MN, respectively), confirming the
idea that the V3 loop is implicated more in coreceptor
interaction than in CD4 binding. A second V3 loop-spe-
cific mAb, 19b, recognizes a conformational epitope on
gp120MN that is not present on gp120IIIB. Similar to 447-
52D, this mAb inhibited the gp120–CXCR4 interaction by
80% without interfering with gp120-CD4 binding. 2G12
binds a unique, relatively conserved gp120 neutralizing
epitope present on gp120IIIB, and C108G reacts with the
V2 loop of gp120IIIB; these two mAbs interfered with
gp120-CXCR4 to an intermediate extent (approximately
40% recovery of 12G5 binding), without influencing the
gp120–CD4 interaction. We tested mAbs to other, non-
neutralizing epitopes for their effect on the sgp120-
CXCR4 interaction. M85 and M86, two non-neutralizing
NH2-terminal-specific mAbs of rat origin (Moore et al.,
1994), had no effect on sgp120 inhibition of 12G5 binding
(data not shown). The gp41-specific mAb 2F5 was used
as an irrelevant antibody control and did not interfere
with the sgp120–CXCR4 interaction (Fig. 5). Thus neutral-
izing mAbs to several distinct epitopes on gp120 inter-
fere with the sgp120–CXCR4 interaction independently of
CD4–sgp120 binding in a manner analogous to that ob-
served for CCR5–gp120 interactions.
Analysis of sgp120 deletion mutants for inhibition of
12G5 binding
It has been reported that conservation of the gp120 V3
loop is required for CCR5 binding, implying that this
region may interact directly with the coreceptor mole-
cules. The potent ability of V3 loop mAbs to interfere with
the gp120–CXCR4 interaction is consistent with the idea
that the same may be true for the gp120–CXCR4 interac-
tion. To investigate the regions of sgp120 potentially
interacting with CXCR4, we compared the ability of wild-
type X4 sgp120HxB2 with forms deleted at the COOH and
NH2 termini and with additional deletion of the V1V2 and
V1V2V3 loops for their ability to interact with CD4 and
CXCR4. Consistent with data obtained with the sgp120
obtained from other viruses, the wild-type sgp120HxB2
FIG. 4. sgp120-CXCR4 interactions on T cell lines. T cell lines
were incubated with 30 mg/ml sgp120IIIB or sgp120MN before divi-
sion into duplicate samples. 12G5 was added directly to one and
Q4120 to the other. Following a further incubation at 4°C, the cells
were washed and bound mAb was detected by indirect immunoflu-
orescence and flow cytometric analysis as for Fig. 1. (A) Inhibition of
12G5 binding by gp120 (means of triplicates 61 SD). (B) Inhibition of
Q4120 binding by gp120. (C) CXCR4 and CD4 membrane expres-
sion on different T cell lines. The cell lines shown were incubated
with the CXCR4-specific mAb 12G5 (5 mg/ml) or CD4 mAb Q4120
(2 mg/ml); mAb binding was detected by indirect immuno-
fluorescent staining and flow cytometric analysis as described for
Fig. 1.
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bound with high affinity to the CD4-CXCR4 complex and
yielded a maximum 12G5 inhibition of about 40% (Fig. 6).
Interestingly, the protein with COOH and NH2 deletions
bound with very similar affinity to CD4 but did not signif-
icantly interfere with 12G5 binding. These data imply that
the COOH and NH2 termini either contribute directly to
the CXCR4 binding site or that their integrity influences
the conformation of gp120 elements important for CXCR4
binding. Further deletion of the V1 and V2 loops resulted
in a molecule that regained its ability to interact with
CXCR4; if the curves are normalized for CD4–CXCR4
affinity, then the sgp120D82DC5DV1V2 mutant interacts with
CXCR4 to a degree similar to that of the wild-type protein.
Additional deletion of the V3 loop (sgp120D82DC5DV1V2V3)
results in a molecule that binds well to CD4 but is unable
interact with CXCR4.
DISCUSSION
Here we show that the interaction of the SU glycopro-
teins of several different HIV-1 viruses and an HIV-2 virus
with cell surface CXCR4 depends on their affinity for the
CD4–CXCR4 complex and that the expression level of
CD4 is limiting. Thus even under conditions in which
essentially all cell surface CD4 molecules were satu-
rated with gp120 and CD4 was in excess over CXCR4,
the maximum inhibition of 12G5 or 6H8 binding observed
was never more than about 50%. These data are consis-
tent with the idea that the sgp120–CD4 interaction is of
higher affinity than the sgp120–CXCR4 interaction, a no-
tion supported by a previous determination of the rela-
tively low intrinsic affinity between sgp120 and CXCR4
(Hesselgesser et al., 1997; Bandres et al., 1998) and by
our inability to demonstrate sgp120 binding to CD42
A2.01 cells in a previous study (Ugolini et al., 1997b). In
this model, a high dissociation rate would mean that
even large amounts of cell-surface-associated gp120
would only be associated with a limited number of
CXCR4 molecules at any one time. Another interpretation
of the weak inhibition of 12G5 binding in the presence of
large amounts of cell-surface-bound sgp120 is that
gp120-CXCR4 binding is competed for by other intermo-
lecular interactions. Thus the CXCR4 binding site on
sgp120 may be occupied by chemokine receptors other
than CXCR4 or other surface structures, such as heparin
sulfate proteoglycans (Roderiquez et al., 1995), that are
present on the surface of the cell lines tested. This
FIG. 5. Reduction in the inhibition of 12G5 binding by gp120-specific mAbs. sgp120IIIB (A and B) or sgp120MN (C and D) were preincubated with a
fivefold molar excess of neutralizing mAb before addition to A3.01 cells. After 4 h at 4°C, either 12G5 (A and C) or Q4120 (B and D) was added. After
washing, the mAbs were detected by indirect immunofluorescence as described for Fig. 1. Bars represents the mean of triplicates 61 SD.
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interpretation is also consistent with a low-affinity inter-
action between sgp120 and CXCR4. In this respect, it is
interesting to note that HIV-2LAV-2 gp105 has an affinity for
sCD4 that is about 10-fold lower than sgp120 from HIV-
1LAI (Moore et al., 1991), whereas the sgp105 affinity for
the CD4–CXCR4 complex, measured by displacing
Q4120, was equivalent to the highest affinity HIV-1
gp120s (Fig. 1). Since gp105 was the most potent inhib-
itor of 12G5 binding, it is tempting to speculate that this
molecule has the highest affinity for CXCR4 and that the
combined affinity for the CD4–CXCR4 complex compen-
sates for the lower intrinsic CD4 affinity. A relatively
elevated intrinsic affinity of HIV-2 gp105 for CXCR4 may
help to explain the rapid, spontaneous appearance of
CD4-independent HIV-2 variants (LAV-2B) in culture
(Clapham et al., 1993; Endres et al., 1996) and may be
analogous to the relatively high affinity of SIVmac for
macaque CCR5 (Martin et al., 1997). By contrast, the
gp120 derived from R5 viruses (Bal, JRFL, and probably
CM235) have affinities for sCD4 that differ by at least
10-fold [Bal, Kd 5 30 nM (Ivey-Hoyle et al., 1991) and
JRFL, Kd 5 3 nM (our unpublished data)] but are all poor
inhibitors of 12G5 binding, implying relatively low intrin-
sic affinities for CXCR4.
Recently, it has been demonstrated that sgp160 can
interact with CD42/CXCR41 Jurkat cells in a CD4-inde-
pendent manner, albeit weakly (Bandres et al., 1998).
One obvious difference between these results and those
from our previous study using A2.01 cells (Ugolini et al.,
1997b) is that Bandres et al. used oligomeric gp160 for
most experiments; oligomerization increases the valency
of CXCR4 binding sites, potentially allowing a detectable
interaction. Differences such as these highlight the im-
portance of discriminating among different forms of Env;
data from several recent studies have shown that the
binding of sgp120 to cells is not fully representative of
the binding of virion-associated Env (Mondor et al., 1998;
Ugolini et al., 1997a). Data generated using soluble forms
of monomeric Env should therefore be interpreted with
some caution. Nevertheless, such studies allow quanti-
tative analyses of SU-receptor complex interactions,
something that is not yet possible with whole virus
assays.
sgp120 molecules of various viral origins induced sim-
ilar levels of binding inhibition of both 12G5, which binds
the second extracellular loop of CXCR4, and 6H8, which
binds the NH2 terminus. This may reflect a global con-
formational change induced by sgp120 in CXCR4 that
interferes with mAb binding to distinct epitopes, interac-
tion of these sgp120 molecules of different viral origin
with both the NH2 and second extracellular domains of
CXCR4, or steric interference of mAb binding by sgp120.
In support of the second hypothesis, it has been dem-
onstrated that certain HIV-1 and HIV-2 isolates require
conservation of both of these regions of CXCR4 for effi-
cient interaction leading to fusion (Brelot et al., 1997). An
analogous result has been obtained with CCR5: the bind-
ing of R5 gp120 to CCR5-expressing cells interferes with
the binding of mAb 2D7 specific for the second extracel-
lular domain of CCR5 (Dragic et al., 1998). Similarly, we
have shown that both 2D7 and 3A9, a mAb specific for
the CCR5 NH2 terminal, are inhibited by R5 sgp120 from
binding to A3.01 cells stably expressing CCR5 (results
not shown).
Neutralizing mAb have been shown to interfere with
the SU–CCR5 interaction independently of the SU–CD4
interaction (Trkola et al., 1996a; Wu et al., 1996; Hill et al.,
1997). Our data confirm that the SU–CXCR4 interaction is
similarly inhibited by neutralizing mAbs to several differ-
ent epitopes. Although we are unable to precisely deter-
mine which epitopes are the most important in the
gp120–CXCR4 interaction from this kind of study, if we
assume that the degree of 12G5 inhibition achieved may
FIG. 6. sgp120, either wild-type HxB2 or HxB2 deleted at the COOH
and NH2 termini (HxB2D 82DC5), the NH2, COOH termini, and the V1V2
loops (HxB2D82DC5DV1V2) or the NH2, COOH termini, and the V1V2 and
V3 loops (HxB2D82DC5DV1V2V3) were incubated with A3.01 cells as de-
scribed for Fig. 1, then divided into two equal samples. To one sample
12G5 was added, to the other, Q4120. After a further incubation at 4°C,
the cells were washed, labeled, and analysed as for Fig. 1. Data points
in (A) are the means of triplicates 61 SD.
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indicate the importance of the epitope in such an inter-
action, then the V3 and CD4i epitopes may be the most
relevant. These results are analogous to those obtained
for the SU–CCR5 interaction: V3 loop and CD4i mAbs
were the most efficient at restoring MIP-1b binding to the
CCR51 cells (Trkola et al., 1996a; Wu et al., 1996). The
finding that mAbs to the same epitope clusters interfere
with both the gp120–CXCR4 and gp120–CCR5 interac-
tions is consistent with the recent demonstration that
neutralization of HIV-1 is not strongly influenced by the
coreceptor used by the virus, at least in terms of CCR5
and CXCR4 (LaCasse et al., 1998; Montefiori et al., 1998;
Trkola et al., 1998).
The V3 loop is a major determinant of viral tropism and
has been shown to be important for HIV–CCR5 interactions
(Choe et al., 1996; Cocci et al., 1996; Wu et al., 1996). We
have attempted to investigate the role of the V3 loop in
sgp120–CXCR4 interactions by using deletion mutants. Our
results demonstrate that whereas a form of gp120 deleted
in the V1 and V2 loops was fully able to interfere with 12G5
binding, further deletion of the V3 loop abrogated 12G5
inhibition without altering CD4 affinity. These data implicate
the V3 loop in SU–CXCR4 interactions. Interpretation is
complicated, however, by the finding that deletion of the
gp120 COOH and NH2 termini also eliminated 12G5 inhibi-
tion without interfering with CD4 binding. Unfortunately
sgp120 deleted solely in the hypervariable loop and not at
the extremities was not available, and thus we are unable
to dissociate indirect effects caused by removal of the first
82 amino acids and the C5 region from effects due solely to
deletion of the V3 loop. Deletion of the extremities of the SU
glycoprotein has not previously been shown to abolish
coreceptor interaction, and it is interesting that the subse-
quent removal of the V1 and V2 loops restores CXCR4
binding activity. The most logical interpretation of these
data are that further removal of the V1/V2 loops compen-
sates for the lack of CXCR4 binding either by restoring a
global SU conformation similar to that of the wild-type
protein or by increasing the exposure of a CXCR4 binding
site that is masked by the V1/V2 loops. A potential candi-
date for such a structure is the CD4-induced epitope,
whose exposure is increased by removal of these loops
(Wyatt et al., 1995). At present it is unclear why deletion of
the COOH and NH2 termini prevents CXCR4 binding. The
two most likely possibilities are that (1) these deletions
cause a distortion of the gp120 conformation that is incom-
patible with coreceptor binding and (2) either or both of the
extremities of gp120 may be involved directly or indirectly in
CXCR4 binding. More detailed mutagenesis studies will be
required to determine which of these two possibilities are
most likely to explain the observed results.
Taken together, our data are consistent with the idea
that the SU–CXCR4 and SU–CCR5 interactions are to a
great extent analogous. The similarities observed be-
tween the sgp120 interactions with these two corecep-
tors will facilitate understanding of the basic mecha-
nisms involved in HIV-coreceptor interactions and help to
design strategies for intervention.
MATERIALS AND METHODS
Cells, antibodies, and sgp120
The human CD41 T cell lines Jurkat, Molt4, SupT1, H9,
and C8166 were from H. Holmes and the MRC AIDS
Reagent Project (National Institute for Biological Stan-
dards and Controls, Potters Bar, UK); A3.01 and its CD42
sister line A2.01 were from T. Folks, Center for Disease
Control, Atlanta, GA; and HPB-ALL was from P. Beverley,
The Edward Jenner Institute for Vaccine Research,
Compton, UK. All lines were grown in RPMI 1640 sup-
plemented with 10% fetal calf serum and antibiotics
(growth medium, GM). The anti-CD4 mouse mAb Q4120
(from the AIDS Reagent Repository, UK) was previously
mapped to the first domain of CD4 (Healey et al., 1990)
and competes with HIV-1 for CD4 binding (Mondor et al.,
1998). The anti-CXCR4 mAb 12G5 (Endres et al., 1996)
recognizes a conformational epitope probably located on
the second extramembranal loop of the molecule (Brelot
et al., 1997; Lu et al., 1997) and inhibits infection and
fusion of certain HIV-1 viruses with certain target cells
(McKnight et al., 1997; Strizki et al., 1997). The 6H8 mAb
was prepared as follows: Balb/c mice were immunized
with a synthetic peptide spanning the first 28 N-terminal
amino acids of CXCR4 coupled via cysteine 28 to ovalbu-
min. Fusions were carried out as previously described
(Tanchou et al., 1995). A first round of screening was by
indirect immunofluorescent staining and flow cytometric
analysis on CEM cells that constitutively express CXCR4.
Positive wells were rescreened as before on CXCR4
transfected and untransfected CHO cells (Oberlin et al.,
1996). 6H8 was cloned from a well positive in both
rounds of screening and after additional phenotyping on
human peripheral blood lymphocytes. The antibody was
determined to be of IgG1 isotype and was purified from
bulk culture supernatant on an anti-IgG affinity column (a
gift from H. Bazin, IMEX Inc., Brussels, Belgium). HIV-1
gp120-specific mAbs of human origin were from the
following sources: 19b [V3 loop (Moore et al., 1995b)] 17b
and 48d [CD4i epitope, (Thali et al., 1993)] from J. Rob-
inson (University of Connecticut, CT); the anti-V3 loop
mAb 447-52D [Gorny et al., 1992; (Conley et al., 1994)]
was purchased from Cellular Products Inc. (Buffalo, NY);
the chimpanzee anti-gp120-V2 mAb C108G, prepared as
previously described (Warrier et al., 1994), was obtained
from S. Tilley (Public Health Research Institute, New
York, NY); the anti-CD4bs monospecific antibody
IgG1b12 (Burton et al., 1994) was from D. Burton (The
Scripps Research Institute, La Jolla, CA); and the human
anti-gp120 mAb 2G12 (Trkola et al., 1995, 1996b) and the
anti-gp41 mAb 2F5 (Muster et al., 1993) were prepared by
H. Katinger and were obtained from the MRC AIDS Re-
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agent project. The mAbs M85 and M86 of rat origin were
prepared by F. di Marzo Veronese (di Marzo Veronese et
al., 1992) and react with epitopes in the C1 region of
gp120 (Moore et al., 1994). HIV-11 human pooled immu-
noglobulins (HIVIg) was prepared by A. Prince (Prince et
al., 1988) and obtained from the National Institutes of
Health (NIH) AIDS Research and Reference Reagent
Program, McKesson BioServices (Rockville, MD). Re-
combinant soluble SU glycoprotein from the HIV-1 vi-
ruses MN, IIIB, SF-2, W61D, and HIV-2 LAV-2ROD were
obtained from the MRC AIDS Reagent Project; CM235
(McCutchan, 1992) was produced by MicroGeneSys Inc.
and was obtained from the NIH AIDS Research and
Reference Reagent Program; Bal sgp120 (Ivey-Hoyle et
al., 1991) was from R. Sweet (SmithKline and Beecham,
King of Prussia, PA); and JRFL sgp120 (Trkola et al.,
1996a) was from G. Allaway and P. Maddon (Progenics,
Raritan, NJ). HxB2 sgp120 and deletion mutants thereof
were prepared as previously described (Wu et al., 1996).
The SU glycoproteins IIIB, HxB2, MN, SF-2, and LAV-2 are
derived from TCLA viruses, W61D is derived from a
primary T cell-tropic HIV-1 isolate (Groenink et al., 1991),
and Bal, JRFL and CM235 are from macrophage-tropic
primary viruses. SU glycoproteins were prepared either
from purified chinese hamster ovary cell supernatants
(IIIB, SF-2, W61D, and JRFL) or from Drosophila cells (MN,
HxB2, CM235, Bal, and LAV-2).
12G5, 6H8, and Q4120 binding and binding-inhibition
studies
A3.01 cells (1.5 3 106) were washed in PBS/1% FCS/
0.01% sodium azide (wash buffer, WB), and incubated in 30
ml WB with varying concentrations of sgp120 for 4 h at 4°C
with agitation. The cells were then divided into three ali-
quots. One of the aliquots was washed twice in WB, HIVIg
at a final concentration of 50 mg/ml was added, the cells
incubated for 1 h at 4°C, washed, and anti-human IgG-
phycoerythrin (Immunotech, Marseille, France) at 1/100 in
WB was added. After incubation for 1 h at 4°C, the cells
were washed and analysed by flow cytometry as described
below. The other two aliquots were not washed, but either
Q4120 at 2 mg/ml or the anti CXCR4 mAb (either 12G5 or
6H8) at 5 mg/ml was added to yield a total volume of 30 ml,
and the cells were incubated for 1 h at 4°C. The cells were
washed twice in WB, fixed overnight at 4°C in 0.5% form-
aldehyde, washed again, then anti-mouse IgG-phyco-
erythrin conjugate (Immunotech) was added at a 1/100
dilution. After a further 1-h incubation at 4°C with agitation,
the cells were washed twice, resuspended in 200 ml of WB,
and analysed by single colour flow cytometry using a FAC-
Scan (Becton Dickinson, San Diego, CA) with Consort 30 or
Lysis II software. Each datum point represents the acqui-
sition of 10,000 gated events. Percentage inhibition was
calculated using the formula 100 2 [(t 2 c]/(m 2 c) 3 100]
where t represents the signal for the test sample, c repre-
sents the background signal in the absence of CXCR4-
specific mAb, and m represents the signal obtained for the
mAb in the absence of inhibitor. The percentage reduction
in inhibition of 12G5 binding induced by precomplexing
anti-gp120 mAbs with gp120 was calculated by taking the
maximum inhibition of 12G5 binding in the presence of
sgp120 as 0%, and no inhibition of 12G5 binding in the
absence of gp120 as 100%. Results were analysed for
correlation as follows. Simple regression of the second
order of linear relationships were performed on datum
points paired for each parameter, carried out as described
in the Statview programme (Abacus, CA). The P values
were calculated with F and Student’s t tests. Indirect immu-
nofluorescent staining of A3.01 cells was carried out by
incubating 3 3 105 cells in 50 ml WB with predetermined
saturating concentrations of either Q4120 (2 mg/ml) or 12G5
(20 mg/ml) for 1 h at 4°C. Cells were washed in WB and
fixed overnight in 0.5% formaldehyde. After washing, cells
were incubated with anti-mouse Ig-phycoerythrin conju-
gate, washed, and analysed by flow cytometry as described
above. The fixing process reduced the absolute mean flu-
orescence intensity of the staining by two- to fourfold, but
the values thus obtained were consistently found to be
proportional to the values obtained with unfixed cells. Some
variability in 12G5 staining was observed between experi-
ments, suggesting either partial modulation of CXCR4 ex-
pression or partial epitope masking. Both CD4 and CXCR4
staining yielded a single peak, demonstrating that 100% of
the cells were positive and relatively homogeneous for
expression of both molecules.
Western blotting of sgp120
One microgram of each sgp120 was migrated on a
reducing SDS 8% polyacrylamide gel, then transferred
to nitrocellulose membranes as previously described
(Moulard et al., 1994). Briefly, immunodetection of the
glycoproteins was performed with 10 mg/ml of HIVIg.
Membranes were then incubated with peroxidase-
conjugated goat anti-human IgG and developed with
the ECL system in accordance with the supplier’s
instructions (Amersham, Les Ulis, France). Goat anti-
human coupled to peroxidase was obtained from Dako
(Trappes, France).
ACKNOWLEDGMENTS
We thank J. Robinson for the kind gifts of mAbs 19b, 48d, and 17b, R.
Sweet for Bal sgp120, and P. Maddon for JRFL sgp120. This study was
supported by the Centre National de la Recherche Scientifique, the
Institute National de la Sante´ et la Recherche Me´dicale, the Agence
Nationale de Recherches sur le SIDA, the Fondation pour la Recherche
Me´dicale (SIDACTION), the European Community Biomed II Shared-
Cost Action Antibody Mediated enhancement and neutralization of
lentivirus infections: role in immune pathogenesis and vaccine devel-
opment. P.J.K. is supported by an MRC fellowship, and A.A. is supported
by a fellowship from Ensemble contre le SIDA.
402 MONDOR ET AL.
REFERENCES
Alkhatib, G., Combadiere, C., Broder, C. C., Feng, Y., Kennedy, P. E.,
Murphy, P. M., and Berger, E. A. (1996). CC CKR5: A rantes, MIP-1a,
MIP-1b receptor as a fusion cofactor for macrophage tropic HIV-1.
Science272, 1955–1959.
Bandres, J. C., Wang, Q. F., O’Leary, J., Baleux, F., Amara, A., Hoxie, J. A.,
Zolla-Pazner, S., and Gorny, M. K. (1998). Human immunodeficiency
virus (HIV) envelope binds to CXCR4 independently of CD4, and
binding can be enhanced by interaction with soluble CD4 or by HIV
envelope deglycosylation. J. Virol. 72, 2500–2504.
Berger, E. A. (1997). HIV entry and tropism: The chemokine receptor
connection. AIDS 11, S3–S16.
Berger, E. A., Doms, R. W., Fenyo, E.-M., Korber, B. T. M., Littman, D. R.,
Moore, J. P., Sattentau, Q. J., Schuitemaker, H., Sodroski, J., and
Weiss, R. A. (1997). HIV-1 phenotypes classified by co-receptor us-
age. Nature 391, 240.
Bleul, C. C., Farzan, M., Choe, H., Parolin, C., Clark-Lewis, I., Sodroski,
J., and Springer, T. A. (1996). The lymphocyte chemoattractant SDF-1
is a ligand for LESTR/fusin and blocks HIV-1 entry. Nature 382,
829–832.
Bour, S., Geleziunas, R., and Wainberg, M. A. (1995). The human immu-
nodeficiency virus type 1 (HIV-1) CD4 receptor and its central role in
promotion of HIV-1 infection. Microbiol. Rev. 59, 63–93.
Brelot, A., Heveker, N., Pleskoff, O., Sol, N., and Alizon, M. (1997). Role
of the first and third extracellular domains of CXCR-4 in human
immunodeficiency virus coreceptor activity. J. Virol. 71, 4744–4751.
Burton, D. R., Pyati, J., Koduri, R., Sharp, S. J., Thornton, G. B., Parren,
P. W., Sawyer, L. S., Hendry, R. M., Dunlop, N., Nara, P. L., and Burton,
D. (1994). Efficient neutralization of primary isolates of HIV-1 by a
recombinant human monoclonal a ntibody. Science 266(5187), 1024–
1027.
Choe, H., Farzan, M., Sun, Y., Sullivan, N., Rollins, B., Ponath, P. D., Wu,
L., Mackay, C. R., LaRosa, G., Newman, W., Gerard, N., Gerard, C.,
and Sodroski, J. (1996). Cell 85, 1135–1148.
Clapham, P., McKnight, A., Simmons, G., and Weiss, R. (1993). Is CD4
sufficient for HIV entry? Cell surface molecules involved in HIV
infection. Philos. Trans. R. Soc. Lond. B Biol. Sci. 342(1299), 67–73.
Clements, G. J., J., P.-J. M., Stephens, P. E., Sutton, C., Schulz, T. F.,
Clapham, P. R., McKeating, J. A., McClure, M. O., Thomson, S., Marsh,
M., Kay, J., Weiss, R. A., and Moore, J. P. (1991). The V3 loops of the
HIV-1 and HIV-2 surface glycoproteins contain proteolytic cleavage
sites: A possible function in viral fusion? AIDS Res. Hum. Retrovi-
ruses 7, 3–16.
Cocci, F., DeVico, A. L., Garzino-Demo, A., Cara, A., Gallo, R. C., and
Lusso, P. (1996). The V3 domain of the HIV-1 gp120 envelope glyco-
protein is critical for chemokine- mediated blockade of infection.
Nature Med. 2, 1244–1247.
Conley, A. J., Gorny, M. K., Kessler, J. A., Boots, L. J., Ossorio-Castro, M.,
Koenig, S., Lineberger, D. W., Emini, E. A., Williams, C., and Zolla-
Pazner, S. (1994). Neutralization of primary human immunodeficiency
virus type 1 isolates by the broadly reactive anti-V3 monoclonal
antibody, 447-52D. J. Virol. 68(11), 6994–7000.
Deng, H., Liu, R., Ellmeier, W., Choe, S., Unutmaz, D., Burkhart, M., Di
Marzio, P., Marmon, S., Sutton, R. E., Hill, C. M., Davis, C. B., Peiper,
S. C., Schall, T. J., Littman, D. R., and Landau, N. R. (1996). Identifi-
cation of a major co-receptor for primary isolates of HIV-1. Nature
381, 661–666.
di Marzo Veronese, F., Rahman, R., Pal, R., Boyer, C., Romano, J.,
Kalyanaraman, V. S., Nair, B. C., Gallo, R. C., and Sarngadharan, M. G.
(1992). Delineation of immunoreactive, conserved regions in the
external envelope glycoprotein of the human immunodeficiency virus
type 1. AIDS Res. Hum. Retroviruses 8, 1125–1132.
Doms, R. W., and Peiper, S. C. (1997). Unwelcomed guests with master
keys: How HIV uses chemokine receptors for cellular entry. Virology
235, 179–190.
Doranz, B., Rucker, J., Yi, Y., Smyth, R. J., Samson, M., Peiper, S. C.,
Parmentier, M., Collman, R. G., and Doms, R. W. (1996). A dual-tropic
primary HIV-1 isolate that uses fusin and the b-chemokine receptors
CKR-5, CKR-3, and CKR-2b as fusion cofactors. Cell 85, 1149–1158.
Dragic, T., Litwin, V., Allaway, G. P., Martin, S. R., Huang, Y., Nagashima,
K. A., Cayanan, C., Maddon, P. J., Koup, R. A., Moore, J. P., and Paxton,
W. A. (1996). HIV-1 entry into CD41 cells is mediated by the chemo-
kine receptor CC-CKR-5. Nature 381, 667–673.
Dragic, T., Trkola, A., Lin, S. W., K. A., N., Kajumo, F., Zhao, L., Olson,
W. C., Wu, L., Mackay, C. R., Allaway, G. P., Sakmar, T. P., Moore, J. P.,
and Maddon, J. P. (1998). Amino-terminal substitutions in the CCR5
coreceptor impair gp120 binding and human immunodeficiency virus
type 1 entry. J. Virol. 72, 279–285.
Endres, M. J., Clapham, P. R., Marsh, M., Ahuja, M., Davis-Turner, J.,
McKnight, A., Thomas, J. F., Stoebenau-Haggarty, B., Choe, S., Vance,
P. J., Wells, T. N. C., Power, C. A., Sutterwala, S. S., Doms, R. W.,
Landau, N. R., and Hoxie, J. A. (1996). CD4-independent infection by
HIV-2 is mediated by Fusin/CXCR-4. Cell 87, 745–765.
Feng, Y., Broder, C. C., Kennedy, P. E., and Berger, E. A. (1996). HIV-1
entry cofactor: Functional cloning of a seven-transmembrane, G
protein-coupled receptor. Science 272, 872–877.
Forster, R., Kremmer, E., Schubel, A., Breitfelld, D., Kleinschmidt, A.,
Nerl, C., Bernhardt, G., and Lipp, M. (1998). Intracellular and surface
expression of the HIV-1 coreceptor CXCR4/Fusin on various leuko-
cyte subsets: Rapid internalization and recycling upon activation.
J. Immunol. 160, 1522–1531.
Gorny, M. K., Conley, S., Karwowska, A., Buchbinder, A., Xu, J.-Y., Emini,
E. A., Koenig, S., and Zolla-Pazner, S. (1992). Neutralization of diverse
human immunodeficiency virus type 1 variants by an anti-V3 human
monoclonal antibody. J. Virol. 66, 7538–7542.
Groenink, M., Fouchier, R. A. M., de Goede, R. E. Y., de Wolf, F., Gruters,
R. A., Cuypers, H. T. M., Huisman, H. G., and Tersmette, M. (1991).
Phenotypic heterogeneity in a panel of infectious molecular human
immunodeficiency virus type 1 clones derived from a single individ-
ual. J. Virol. 65, 1968–1975.
Healey, D., Dianda, L., Moore, J. P., McDougal, J. S., Moore, M. J., Estess,
P., Buck, D., Kwong, P. D., Beverley, P. C. L., and Sattentau, Q. J. (1990).
Novel anti-CD4 monoclonal antibodies separate human immunode-
ficiency virus infection and fusion of CD41 cells from virus binding.
J. Exp Med. 172, 1233–1242.
Hesselgesser, J., Halks-Miller, M., DelVeccio, V., Peiper, S. C., Hoxie, J.,
Kolson, D. L., Taub, D., and Horuk, R. (1997). CD4-independent as-
sociation between HIV-1 gp120 and CXCR4: Functional chemokine
receptors are expressed in human neurons. Curr.Biol. 7, 112–121.
Hill, C. M., Deng, H., Unutmaz, D., Kewalramani, V. N., Bastiani, L.,
Gorny, M. K., Zolla-Pazner, S., and Littman, D. R. (1997). Envelope
glycoproteins from human immunodeficiency virus types 1 and 2 and
simian impmunodeficiency virus can use human CCR5 as a core-
ceptor for viral entry and make direct CD4-dependent interactions
with this chemokine receptor. J. Virol. 71, 6296–6304.
Ivey-Hoyle, M., Culp, J. S., Chaikin, M. A., Hellmig, B. D., Matthews, T. J.,
Sweet, R. W., and Rosenberg, M. (1991). Envelope glycoproteins from
biologically diverse isolates of human immunodeficiency viruses
have widely different affinities for CD4. Proc. Natl. Acad. Sci. USA 88,
512–516.
LaCasse, R. A., Follis, K. E., Moudgil, T., Trahey, M., Binley, J., Planelles,
V., Zolla-Pazner, S., and Nunberg, J. H. (1998). Coreceptor utilization
by human immunodeficiency virus type 1 is not a primary determi-
nant of neutralization sensitivity. J. Virol. 72, 2491–2495.
Lapham, C. K., Ouyang, J., Chandrasekhar, B., Kguyen, N. Y., Dimitrov,
D. S., and Golding, H. (1996). Evidence for cell-surface association
between fusin and the CD4- gp120 complex in human cell lines.
Science 274, 602–605.
Levy, J., Ed. (1994). ‘‘HIV and the pathogenesis of AIDS.’’ American
Society for Microbiology, Washington, D.C.
Liu, R., Paxton, W. A., Choe, S., Ceradini, D., Martin, S. R., Horuk, R.,
MacDonald, M. E., Stuhlmann, H., Koup, R. A., and Landau, N. R.
(1996). Homozygous defect in HIV-1 coreceptor accounts for resis-
403CD4-DEPENDENT gp120–CXCR4 INTERACTIONS
tance of some multiply exposed individuals to HIV-1 infection. Cell
86, 367–377.
Lu, Z., Berson, J. F., Chen, Y., Turner, J. D., Zhang, T., Sharron, M., Jenks,
M. H., Wang, Z., Kim, J., Rucker, J., Hoxie, J. A., Peiper, S. C., and
Doms, R. W. (1997). Evolution of HIV-1 coreceptor usage through
interactions with distinct CCR5 and CXCR4 domains. Proc. Natl.
Acad. Sci. USA 94, 6426–6431.
Martin, K. A., Wyatt, R., Farzan, M., Choe, H., Marcon, L., Desjardins, E.,
Robinson, J., Sodroski, J., Gerard, C., and Gerard, N. P. (1997). CD4-
independent binding of SIV gp120 to rhesus CCR5. Science 278,
1470–1472.
McCutchan, F. E., Hegerich, P. A., Brennan, T. P., Phanuphak, P., Sing-
haraj, P., Jugsudee, A., Berman, P. W., Gray, A. M., Fowler, A. K., and
Burke, D. S. (1992). Genetic variants of HIV-1 in Thailand. AIDS Res.
Hum. Retroviruses 8, 1887–1895.
McKnight, A., Wilkinson, D., Simmons, G., Picard, L., Ahuja, M., Marsh,
M., Hoxie, J. A., and Clapham, P. R. (1997). Inhibition of HIV fusion by
a monoclonal antibody to a co-receptor (Lestr) is both cell type and
virus strain dependent. J. Virol. 71, 1692–1696.
Mondor, I., Ugolini, S., and Sattentau, Q. J. (1998). HIV-1 attachment to
HeLa CD4 cells is CD4-independent, gp120 dependent and requires
cell surface heparans. J. Virol. 72, 3623–3634.
Montefiori, D. C., Collman, R. G., Fouts, T. R., Zhou, J. Y., Bilska, M.,
Hoxie, J. A., Moore, J. P., and Bolognesi, D. P. (1998). Evidence that
antibody-mediated neutralization of human immunodeficiency virus
type 1 by sera from infected individuals is independent of coreceptor
usage. J. Virol. 72, 1886–1893.
Moore, J. P., Cao, Y., Qing, L., Sattentau, Q. J., Pyati, J., Koduri, R.,
Robinson, J., Barbas, C. F. r., Burton, D. R., and Ho, D. D. (1995a).
Primary isolates of human immunodeficiency virus type 1 are rela-
tively resistant to neutralization by monoclonal antibodies to gp120,
and their neutralization is not predicted by studies with monomeric
gp120. J. Virol. 69, 101–109.
Moore, J. P., Jameson, B. A., Weiss, R. A., and Sattentau, Q. J. (1993). The
HIV-cell fusion reaction. In ‘‘Viral Fusion Mechanisms’’ (J. Bentz, Ed.),
pp. 233–291. CRC Press, Boca Raton.
Moore, J. P., Morikawa, Y., and Jones, I. M. (1991). Binding of recombi-
nant HIV-1 and HIV-2 SU glycoproteins to sCD4. J. Acquired Immune
Def. Syndr. 4, 442–449.
Moore, J. P., Sattentau, Q. J., Wyatt, R., and Sodroski, J. (1994). Probing
the structure of the human immunodeficiency virus surface glyco-
protein gp120 with a panel of monoclonal antibodies. J. Virol. 68(1),
469–484.
Moore, J. P., Trkola, A., and Dragic, T. (1997). Co-receptors for HIV-1
entry. Curr. Opin. Immunol. 9, 551–562.
Moore, J. P., Trkola, A., Korber, B., Boots, L. J., Kessler, J. A. N., Mc-
Cutchan, F. E., Mascola, J., Ho, D. D., Robinson, J., and Conley, A. J.
(1995b). A human monoclonal antibody to a complex epitope in the
V3 region of gp120 of human immunodeficiency virus type 1 has
broad reactivity within and outside clade B. J. Virol. 69(1), 122–130.
Moulard, M., Achstetter, T., Montagnier, L., Kieny, M.-P., and Bahraoui, E.
(1994). Kex2p: A model for cellular endoprotease processing of the
HIV-1 envelope glycoprotein precursor. Eur. J. Biochem. 225, 565–
572.
Muster, T., Steindl, F., Purtscher, M., Trkola, A., Klima, A., Himmler, G.,
Ruker, F., and Katinger, H. (1993). A conserved neutralizing epitope on
gp41 of human immunodeficiency virus type 1. J. Virol. 67(11), 6642–
6647.
Oberlin, E., Amara, A., Bachelerie, F., Bessia, C., Virelizier, J.-L.,
Arenzana-Seisdedos, F., Schwartz, O., Heard, J.-M., Clark-Lewis, I.,
Legler, D. F., Loetscher, M., Baggiolini, M., and Moser, B. (1996). The
CXC chemokine SDF-1 is the ligand for LESTR/fusin and prevents
infection by T-cell-line-adapted HIV-1. Nature 382, 833–835.
Paxton, W. A., Martin, S. R., Tse, D., O’Brien, T. R., Skurnik, J.,
VanDevanter, N. L., Padian, N., Braun, J. F., Kotler, D. P., Wolinsky,
S. M., and Koup, R. A. (1996). Relative resistance to HIV-1 infection of
CD4 lymphocytes from persons who remain uninfected despite mul-
tiple high-risk sexual exposures. Nat. Med. 2, 412–417.
Prince, A. M., Horowitz, B., Baker, L., Schulman, R. W., Ralph, H.,
Valinski, J., Cundell, A., Brotman, B., Boehle, W., Rey, F., Piet, M.,
Reesink, H., Lelie, N., Tersmette, M., Barbosa, L., Nemo, G., Nastala,
C. L., Allan, J. S., Lee, D. R., and Eichberg, J. W. (1988). Failure of a
human immunodeficiency virus (HIV) immune globulin to protect
chimpanzees against experimental challenge with HIV. Proc. Natl.
Acad. Sci. USA 85, 6944–6948.
Roderiquez, G., Oravecz, T., Yanagishita, M., Bou-Habib, D. C.,
Mostowski, H., and Norcross, M. A. (1995). Mediation of human
immunodeficiency virus type 1 binding by interaction of cell surface
heparan sulfate proteoglycans with the V3 region of envelope gp120-
gp41. J. Virol. 69, 2233–2239.
Samson, M., Libert, F., Doranz, B. J., Rucker, J., Liesnard, C., Farber,
C.-M., Saragosti, S., Lapoumerouli, C., Cognaux, J., Forceille, C.,
Muyldermans, G., Verhofstede, C., Burtonboy, G., Georges, M., Imai,
T., Rana, S., Yi, Y., Smyth, R. J., Collman, R. G., Doms, R. W., Vassart,
G., and Parmentier, M. (1996). Resistance to HIV-1 infection in cau-
casian individuals bearing mutant alleles of the CCR-5 chemokine
receptor gene. Nature 382, 722–725.
Sattentau, Q. J., and Moore, J. P. (1993). The role of CD4 in HIV binding
and entry. Philos. Trans. R. Soc. Lond. B Biol. Sci. 342(1299), 59–66.
Sattentau, Q. J., and Moore, J. P. (1995). Human immunodeficiency virus
type 1 neutralization is determined by epitope exposure on the gp120
oligomer. J. Exp. Med. 182, 185–196.
Sattentau, Q. J., and Weiss, R. A. (1988). The CD4 antigen: Physiological
ligand and HIV receptor. Cell 52, 631–632.
Signoret, N., Poignard, P., Blanc, D., and Sattentau, Q. J. (1993). Human
and simian immunodeficiency viruses: Virus-receptor interactions.
Trends Microbiol. 1, 328–333.
Sol, N., Ferchal, F., Braun, J., Pleskoff, O., Tre´boute, C., Ansart, I., and
Alizon, M. (1997). Usage of the coreceptors CCR-5, CCR-3 and CXCR4
by primary and cell line-adapted human immunodeficiency virus type
2. J. Virol. 71, 8237–8244.
Strizki, J. M., Turner, J. D., Collman, R. G., Hoxie, J., and Gonzalez-
Scarano, F. (1997). A monoclonal antibody (12G5) directed against
CXCR4 inhibits infection with the dual- tropic human immunodefi-
ciency virus type 1 HIV-1 89.6 but not the T-tropic isolate HIV-1 HxB2.
J. Virol. 71, 5678–5683.
Sullivan, N., Sun, Y., Sattentau, Q. J., Thali, M., Wu, D., Denisova, G.,
Gershoni, J., Robinson, J., Moore, J., and Sodroski, J. (1998). CD4-
induced conformational changes in the human immunodeficiency
virus type 1 gp120 glycoprotein: consequences for virus entry and
neutralization. J. Virol. 72, 4694–4703.
Sweet, R. A., Truneh, A., and Hendrickson, W. A. (1991). CD4: Its
structure, role in immune function and AIDS pathogenesis, and
potential as a pharmacological target. Curr. Opin. BioTechnol. 2,
622–633.
Tanchou, G., Delauney, T., Bodeus, M., Roques, B. P., Darlix, J.-L., and
Benarous, R. (1995). Conformational changes between human immu-
nodeficiency virus type 1 nucleocapsid protein Ncp7 and its precur-
sor Ncp15 as detected by anti-Ncp7 monoclonal antibodies. J. Gen.
Virol. 76, 2457–2466.
Thali, M., Moore, J. P., Furman, C., Charles, M., Ho, D. D., Robinson, J.,
and Sodroski, J. (1993). Characterization of conserved human immu-
nodeficiency virus type 1 gp120 neutralization epitopes exposed
upon gp120-CD4 binding. J. Virol. 67(7), 3978–3988.
Trkola, A., Dragic, T., Arthos, J., Binley, J. M., Olson, W. C., Allaway, G. P.,
Cheng-Mayer, C., Robinson, J., Maddon, P. J., and Moore, J. P. (1996a).
CD4-dependent, antibody sensitive interactions between HIV-1 and
its co-receptor CCR-5. Nature 384, 184–187.
Trkola, A., Ketas, T., Kewalramani, V. N., Endorf, F., Binley, J., Katinger,
H. R., J., Littman, D. R., and Moore, J. P. (1998). Neutralization sensi-
tivity of human immunodeficiency virus type 1 primary isolates to
antibodies and CD4-based reagents is independent of coreceptor
usage. J. Virol. 72, 1876–1885.
404 MONDOR ET AL.
Trkola, A., Pomales, A. B., Yuan, H., Korber, B., Maddon, P. J., Allaway,
G. P., Katinger, H., Barbas C. F., III, Burton, D., Ho, D. D., and Moore,
J. P. (1995). Cross-clade neutralization of primary isolates of human
immunodeficiency virus type 1 by human monoclonal antibodies and
tetrameric CD4-IgG. J. Virol. 69, 6609–6617.
Trkola, A., Purtscher, M., Muster, T., Ballaun, C., Buchacher, A., Sullivan,
N., Srinivasan, K., Sodroski, J., Moore, J., and Katinger, H. (1996b).
Human monoclonal antibody 2G12 defines a distinctive neutraliza-
tion epitope on the gp120 glycoprotein of human immunodeficiency
virus type 1. J. Virol. 70, 1100–1108.
Ugolini, S., Mondor, I., Parren, P. W. H. I., Burton, D. R., Tilley, S., Klasse,
P.-J., and Sattentau, Q. J. (1997a). Inhibition of virus attachment to
CD41 target cells is a major mechanism of T cell line-adapted HIV-1
neutralization. J. Exp. Med. 186, 1287–1298.
Ugolini, S., Moulard, M., Mondor, I., Barois, N., Demandolx, D., Hoxie, J.,
Brelot, A., Alizon, M., Davoust, J., and Sattentau, Q. J. (1997b). HIV-1
gp120 binding to CD41 cells induces an interaction between CD4,
gp120 and the chemokine receptor CXCR415. J. Immunol. 9, 3000–3008.
Warrier, S. V., Pinter, A., Honnen, W. J., Girard, M., Muchmore, E., and
Tilley, S. A. (1994). A novel, glycan-dependent epitope in the V2
domain of human immunodeficiency virus type 1 gp120 is recog-
nised by a highly potent, neutralizing chimpanzee monoclonal anti-
body. J. Virol. 68, 4636–4642.
Wu, L., Geradr, N. P., Wyatt, R., Choe, H., Parolin, C., Ruffing, N., Borsetti, A.,
Cardoso, A. A., Desjardin, E., Newman, W., Gerard, C., and Sodroski, J.
(1996). CD4-induced interaction of primary HIV-1 gp120 glycoproteins
with the chemokine receptor CCR-5. Nature 384, 179–183.
Wyatt, R., Moore, J., Accola, M., Desjardin, E., Robinson, J., and
Sodroski, J. (1995). Involvement of the V1/V2 variable loop struc-
ture in the exposure of human immunodeficiency virus type 1
gp120 epitopes induced by receptor binding. J. Virol. 69, 5723–
5733.
405CD4-DEPENDENT gp120–CXCR4 INTERACTIONS
